Bio-Techne

377 articles about Bio-Techne

• Bio-Techne Launches New Turbo CE-SDS™ Cartridge, Accelerating Protein Purity Analysis Throughput by 400%

  7/12/2022

  Bio-Techne Corporation announced that ProteinSimple, a Bio-Techne brand, has launched the innovative Maurice™ Turbo CE-SDS cartridge.

• Bio-Techne Announces Launch of the CE-IVD RNAscope™ ISH Probe High Risk HPV Assay for Head and Neck Cancer

  7/6/2022

  Bio-Techne today announced the European launch of the CE-IVD marked RNAscope ISH Probe High Risk HPV, intended for use in patients diagnosed with oropharyngeal squamous cell carcinoma (OPSCC) to aid in the identification of high-risk human papillomavirus (HPV).

• BIO-TECHNE ANNOUNCES COMPLETION OF NAMOCELL ACQUISITION

  7/5/2022

  Bio-Techne Corporation (NASDAQ:TECH), today announced it has completed the acquisition of Namocell, Inc.

• BIO-TECHNE TO ACQUIRE NAMOCELL

  6/22/2022

  Bio-Techne Corporation (NASDAQ:TECH), a global life sciences company providing innovative tools and bioactive reagents for the research and clinical diagnostic communities, today announced it has reached an agreement to acquire Namocell, Inc.

• Bio-Techne Celebrates 40,000 Unique RNAscope™ in situ Hybridization Probes, Targeting Any Gene, Any Tissue, Any Species.

  5/26/2022

  Bio-Techne Corporation (NASDAQ: TECH) today announced Advanced Cell Diagnostics (ACD), a brand of Bio-Techne, reached an extraordinary milestone of developing over 40,000 unique RNAscope in situ Hybridization (ISH) probes in over 400 species.

• BIO-TECHNE TO PRESENT AT THE JEFFERIES HEALTHCARE CONFERENCE

  5/19/2022

  Bio-Techne Corporation (NASDAQ: TECH) today announced that Chuck Kummeth , President and Chief Executive Officer, will present at the Jefferies 2022 Healthcare Conference on Wednesday, June 8, 2022 , at 9:30 a.m. EDT.

• Bio-Techne and Nonagen Bioscience Announce Exclusive Supply Agreement for Nonagen's Oncuria® Bladder Cancer Test

  5/12/2022

  Bio-Techne Corporation (NASDAQ: TECH) and Nonagen Bioscience  today announced an agreement for R&D Systems, a Bio-Techne brand, to exclusively manufacture Nonagen Bioscience's Oncuria ® bladder cancer diagnostic panel using xMAP Luminex ® technology.

• Bio-Techne To Present At Annual American Urological Association Conference In New Orleans

  5/10/2022

  Bio-Techne Corporation announced that Exosome Diagnostics, a Bio-Techne brand, will have a major scientific presence at the annual American Urological Association Conference taking place May 13-16 in New Orleans, LA.

• Bio-Techne Releases Third Quarter Fiscal 2022 Results

  5/4/2022

  Bio-Techne Corporation reported its financial results for the third quarter ended March 31, 2022.

• Bio-Techne Declares Dividend - May 04, 2022

  5/4/2022

  Bio-Techne Corporation announced that its Board of Directors has decided to pay a dividend of $0.32 per share for the quarter ended March 31, 2022.

• Bio-Techne To Present at the BofA Securities Healthcare Conference

  5/2/2022

  Bio-Techne Corporation announced that Chuck Kummeth, President and Chief Executive Officer, will present at the BofA Securities 2022 Healthcare Conference on Wednesday, May 11, 2022, at 2:40 p.m. PST.

• BIO-TECHNE TO HOST CONFERENCE CALL ON MAY 4, 2022, TO ANNOUNCE THIRD QUARTER 2022 FINANCIAL RESULTS

  4/13/2022

  Bio-Techne Corporation (NASDAQ: TECH) today announced that management will host a conference call and webcast on Wednesday, May 4, 2022 , at 8:00 a.m. CDT to review third quarter fiscal 2022 financial results.

• Bio-Techne and Cygnus Technologies, Part of Maravai Lifesciences, Introduce New Simple Plex HEK 293 HCP 3G Immunoassay

  4/12/2022

  Bio-Techne Corporation and Cygnus Technologies, part of Maravai LifeSciences, announced the launch of the Simple Plex™ HEK 293 HCP 3G assay for automated process impurity testing on the Ella™ immunoassay platform.

• Bio-Techne To Present At The Keybanc Life Sciences & Medtech Investor Forum

  3/17/2022

  Bio-Techne Corporation announced that Will Geist, President, Protein Sciences Segment, will present at the KeyBanc Life Sciences & MedTech Investor Forum on Wednesday, March 23, 2022, at 11:15 a.m. EDT.

• BIO-TECHNE TO PRESENT AT THE COWEN 42ND ANNUAL HEALTH CARE CONFERENCE

  2/28/2022

  Bio-Techne Corporation (NASDAQ: TECH) today announced that Jim Hippel , Executive Vice President and Chief Financial Officer, will present at the Cowen 42nd Annual Health Care Conference on Monday, March 7, 2022 , at 11:10 a.m. EST.

• Bio-Techne To Present At The Citi 2022 Virtual Healthcare Conference

  2/22/2022

  Bio-Techne Corporation announced that Jim Hippel, Executive Vice President and Chief Financial Officer, will present at the Citi 2022 Virtual Healthcare Conference on Thursday, February 24, 2022, at 10:15 a.m. EST.

• Bio-Techne Announces Exclusive Development And License Agreement With Thermo Fisher Scientific For ExoTRU® Kidney Transplant Rejection Assay

  2/22/2022

  Bio-Techne Corporation announced an agreement with Thermo Fisher Scientific to exclusively complete development of and commercialize the ExoTRU kidney transplant rejection test developed by Exosome Diagnostics, a Bio-Techne brand.

• BIO-TECHNE ANNOUNCES PUBLICATION OF NEW DATA DEMONSTRATING EXODX PROSTATE TEST CORRELATION WITH POST-PROSTATECTOMY PATHOLOGY OUTCOMES

  2/14/2022

  Bio-Techne Corporation (NASDAQ:TECH) today announced an important publication in World Journal of Urology.

• Bio-Techne To Present At The 11th Annual SVB Leerink Global Healthcare Conference

  2/11/2022

  Bio-Techne Corporation announced that Chuck Kummeth, President and Chief Executive Officer, will present at the 11th Annual SVB Leerink Global Healthcare Conference on Thursday, February 17, 2022, at 9:20 a.m. EST.

• BIO-TECHNE RELEASES SECOND QUARTER FISCAL 2022 RESULTS

  2/1/2022

  Bio-Techne Corporation (NASDAQ: TECH) today reported its financial results for the second quarter ended December 31, 2021 .